What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime...

BioSpace: As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Manufacturer: Ferring / Seikagaku Proposed indications Radicular leg pain associated with lumbar disc herniation (LDH) Clinical overview Mechanism of action Condoliase, also known as chondroitin...

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Manufacturer: Abeona Proposed indications Recessive dystrophic epidermolysis bullosa (RDEB) Clinical overview Mechanism of action Prademagene zamikeracel (pz-cel) is an autologous, collagen type...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...

cover image for Quarterly Drug Pipeline: January 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2026...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Prime Therapeutics researchers share more about award-winning real-world research

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

Specialty Pharmacy Continuum

Managed Healthcare Executive

Academy of Managed Care Pharmacy (AMCP)

BioPharma Dive: There are no drugs specifically for polycystic ovary syndrome, a chronic condition that can cause infertility. One study is testing whether Wegovy might be beneficial.

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

Star Tribune

Editor's message Gene therapy= Aims to fix a faulty gene or replace it with a healthy gene to try to cure a disease or help the body become better at fighting disease Maryam Tabatabai, PharmD...

Shortages in the manufacturing chain have led to label hopping and an increase in off-label use

In the latest episode of the “Pharmacy Friends” podcast, hear about a new clinical report from Prime Therapeutics that dives into the latest evidence-based insights related to the rising prevalence...

According to an analysis led by US-based Prime Therapeutics and published in the Journal of Managed Care & Specialty Pharmacy in August, on average only one-third of people continue taking GLP-1...

CNN: At 37:03, listen to fitness expert Jillian Michaels cite Prime/Magellan Rx research on a podcast recording of a June 21 CNN broadcast

Prime’s industry-leading research on GLP-1s was recognized at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting in Houston

Quarterly Drug Pipeline: January 2024 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2024 About Prime...

Quarterly Drug Pipeline: April 2024 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2024 About Prime...

Quarterly Drug Pipeline: July 2024 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2024 About Prime Therapeutics...

Cover for 2023 January Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jan?fr=sODMzODc3NDc1ODQ About...

Cover for 2023 April Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_apr?fr=xKAE9_zU1NQ About Prime...

Cover for 2023 July Quarterly Pipeline a view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jul?fr=sMjFiMTc3NDc1ODQ About...

Cover for 2023 October Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_oct?fr=sMTIyZTc3NDc1ODQ About...

Forbes

Academy of Managed Care Pharmacy (AMCP)'s Annual Meeting gathers thousands of health plan, pharmacy benefit management and biopharmaceutical experts to help define the future of managed care pharmacy.

Specialty Pharmacy Continuum

cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...

Forbes

Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

U.S. News & World Report

Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. Shortage updates The U.S. Government Accountability Office (GAO) has published a report on drug...

Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...

In the latest episode of the “Pharmacy Friends” podcast, hear from Prime Therapeutics experts about how the fast-moving pipeline is changing how patients, providers and payers prepare for...

PUBLICATIONS FDA Decisions Expected: August 2025 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References Press release:...

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Journal of Managed Care & Specialty Pharmacy (JMCP)

Unlock high-touch outreach Help members and their prescribers make better decisions about medicines through this clinical intelligence hub that delivers actionable insights, flexible levels of data...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

A roundup of Prime's award-winning presentations and insights at AMCP Annual Meeting in Houston

In the latest episode of the “Pharmacy Friends” podcast, join Prime’s research team for a preview of the industry-leading and award-winning research that will be presented at flagship industry event